Conditional marketing authorization is based on clinically meaningful response rates, duration of response, and safety from the Phase 2 MagnetisMM-3 trial
The acquisition will enable Cupid Limited to amplify its production capacity by 1.5 times the existing output
STABILIZE-CKD and DIALIZE-Outcomes trials are part of the CRYSTALIZE evidence programme
Carmot Therapeutics’s R&D portfolio of clinical stage incretins has great potential to treat obesity, diabetes and potentially other diseases
The CAPSUL solution enables optimal process performance for production of premier quality PCL grades at competitive rates
Equipped with most advanced Distributed Control System (DCS) automation technology, the facility has been set up with an investment of Rs. 200 crore
The divestment is a part of Fortis' ongoing portfolio rationalization strategy
Evinova will operate as a separate health-tech business within AstraZeneca
Approval based on results from the Phase 3 KEYNOTE-859 trial, which demonstrated significant improvement in overall survival in these patients versus chemotherapy alone
Expanded collaboration with Vanguard Renewables aims to significantly increase the productivity of US renewable natural gas generation
Subscribe To Our Newsletter & Stay Updated
